EX-99.1 2 a14-4468_1ex99d1.htm EX-99.1

Exhibit 99.1

 

 

 

January 28, 2014

Media Contact:

Patty Seif

WILMINGTON, Del.

 

302-774-4482

 

 

patricia.r.seif@dupont.com

 

Investor Contact:

302-774-4994

 

DuPont Reports 4Q and Full-Year 2013 Operating EPS of $.59 and $3.88;

4Q Segment Operating Earnings Grow 52 Percent on Higher Volume, Improved Operating Margins

 

Company Expects 2014 Operating Earnings of $4.20-$4.45 Per Share;

Separately Announces Multi-Year $5 Billion Share Repurchase Program

 

WILMINGTON, Del., Jan. 28, 2014 — DuPont today announced fourth quarter 2013 operating earnings of $.59 per share compared to $.20 per share in the prior year.  GAAP1 earnings from continuing operations were $183 million or $.19 per share, versus $4 million or zero per share last year.  Fourth quarter results reflect strong volume growth, improved operating margins and a lower base tax rate compared to the prior year.

 

The company said that it expects full-year 2014 operating earnings of $4.20 to $4.45 per share, up 8 to 15 percent versus 2013. DuPont separately announced that its Board of Directors authorized a new $5 billion share repurchase program, with $2 billion expected to occur in 2014.

 

“Our strong fourth quarter results reflect successful execution across the company against the backdrop of a gradually improving global economy,” said DuPont Chair and CEO Ellen Kullman.  “For the year, we delivered double-digit operating earnings growth and higher margins, aside from the substantial decline in Performance Chemicals. The improvement was driven by higher volumes, new innovative products and productivity gains.”

 

“Our 2013 results and strategic actions demonstrate we are advancing our plan to build a higher growth, higher value DuPont and reinforce our decision to separate Performance Chemicals into a strong, independent company,” Kullman said.  “Our $5 billion share repurchase program reflects ongoing confidence in our plan to continue increasing the value of DuPont for shareholders in 2014 and beyond.”

 

Fourth Quarter Highlights

 

·                  Company sales increased 6 percent to $7.7 billion, with 9 percent volume growth reflecting increased demand across all segments and regions.

 

·                  Segment operating earnings of $939 million increased 52 percent versus $616 million last year, with operating margin improvement across most segments.

 

·                  Agriculture operating earnings were $88 million compared to a seasonal operating loss of $77 million last year, driven by strong insecticide sales in Latin America and earlier seed shipments.

 

·                  Electronics & Communications, Safety & Protection and Nutrition & Health recorded operating earnings increases of 116 percent, 57 percent, and 40 percent, respectively.

 


(1)Generally Accepted Accounting Principles (GAAP)

 

E. I. du Pont de Nemours and Company

 



 

Full Year Highlights

 

·                  2013 operating earnings were $3.88 per share, up 3 percent from $3.77 per share in the prior year.  Sales increased 3 percent to $35.7 billion with 5 percent higher volume.  GAAP earnings from continuing operations were $3.04 per share versus $2.59 per share last year.

 

·                  Segment operating earnings were $5.9 billion, down from $6.3 billion last year primarily due to a $0.8 billion decline ($.66 per share) in Performance Chemicals.  Excluding Performance Chemicals in both years, segment operating earnings increased $490 million, or 11 percent.

 

·                  Agriculture operating earnings grew 16 percent on 13 percent higher sales, partially offset by higher seed input costs and negative currency impact.  Sales growth was principally driven by higher global seed prices and volumes, increased global insecticide and fungicide volumes, and the benefit of increased ownership in Pannar Seed (Pty) Ltd.

 

·                  Free cash flow was $1.3 billion versus $3.1 billion in the prior year, primarily due to the decline in Performance Chemicals earnings, changes in Agriculture working capital, and the absence of Performance Coatings earnings following the 2013 divestiture.

 

·                  The unfunded pension and OPEB liability decreased $4.9 billion to $8.4 billion at December 31, 2013.

 

Global Consolidated Net Sales — 4th Quarter

 

Fourth quarter 2013 net sales of $7.7 billion increased 6 percent versus last year, reflecting 9 percent higher volume, partly offset by 2 percent lower local selling prices and a 1 percent negative currency impact.  The table below shows fourth quarter regional sales and variances versus fourth quarter 2012.

 

 

 

Three Months Ended
December 31, 2013

 

Percentage Change Due to:

 

 

 

(Dollars in millions)

 

$

 

% Change

 

Local
Price

 

Currency
Effect

 

Volume

 

Portfolio/
Other

 

U.S. & Canada

 

$

2,648

 

4

 

(3

)

 

8

 

(1

)

EMEA*

 

1,757

 

11

 

(1

)

3

 

6

 

3

 

Asia Pacific

 

1,987

 

2

 

(5

)

(4

)

11

 

 

Latin America

 

1,355

 

8

 

 

(4

)

12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Consolidated Sales

 

$

7,747

 

6

 

(2

)

(1

)

9

 

 

 


* Europe, Middle East & Africa

 

2



 

Segment Sales — 4th Quarter

 

The table below shows fourth quarter 2013 segment sales with related variances versus the fourth quarter 2012.

 

 

 

Three Months Ended
December 31, 2013

 

Percentage Change
Due to:

 

SEGMENT SALES
(Dollars in millions)

 

$

 

% Change

 

USD
Price

 

Volume

 

Portfolio/
Other

 

Agriculture

 

$

1,806

 

18

 

 

14

 

4

 

Electronics & Communications

 

642

 

3

 

(14

)

17

 

 

Industrial Biosciences

 

326

 

9

 

 

9

 

 

Nutrition & Health

 

872

 

2

 

2

 

2

 

(2

)

Performance Chemicals

 

1,616

 

2

 

(10

)

12

 

 

Performance Materials

 

1,576

 

3

 

(2

)

6

 

(1

)

Safety & Protection

 

975

 

1

 

 

1

 

 

Other

 

1

 

nm

 

 

 

 

 

 

 

Total segment sales

 

7,814

 

 

 

 

 

 

 

 

 

Elimination of transfers

 

(67

)

 

 

 

 

 

 

 

 

Consolidated net sales

 

$

7,747

 

 

 

 

 

 

 

 

 

 

Operating Earnings — 4th Quarter

 

 

 

 

 

 

 

Change vs. 2012

 

(Dollars in millions)

 

4Q13

 

4Q12

 

$

 

%

 

Agriculture

 

$

88

 

$

(77

)

$

165

 

214

%

Electronics & Communications

 

93

 

43

 

50

 

116

%

Industrial Biosciences

 

40

 

41

 

(1

)

-2

%

Nutrition & Health

 

81

 

58

 

23

 

40

%

Performance Chemicals

 

229

 

236

 

(7

)

-3

%

Performance Materials

 

295

 

273

 

22

 

8

%

Safety & Protection

 

209

 

133

 

76

 

57

%

Other

 

(101

)

(100

)

(1

)

nm

 

 

 

934

 

607

 

327

 

54

%

Pharmaceuticals

 

5

 

9

 

(4

)

-44

%

Total segment operating earnings (1)

 

939

 

616

 

323

 

52

%

 

 

 

 

 

 

 

 

 

 

Corporate expenses

 

(191

)

(215

)

24

 

nm

 

Interest expense

 

(108

)

(117

)

9

 

nm

 

Operating earnings before income taxes and exchange gains/losses

 

640

 

284

 

356

 

125

%

Provision for income taxes on operating earnings, excluding taxes on exchange gains/losses

 

(43

)

(61

)

18

 

nm

 

Net after-tax exchange gains (losses) (2)

 

(39

)

(29

)

(10

)

nm

 

Net income attributable to noncontrolling interests

 

 

(1

)

1

 

nm

 

Operating earnings

 

$

558

 

$

193

 

$

365

 

189

%

 

 

 

 

 

 

 

 

 

 

Operating earnings per share

 

$

0.59

 

$

0.20

 

$

0.39

 

195

%

 


(1)  See Schedules B and C for listing of significant items and their impact by segment.

(2)  See Schedule D for additional information on exchange gains and losses.

 

3



 

Global Consolidated Net Sales — Full Year

 

Full-year 2013 net sales of $35.7 billion increased 3 percent versus last year, reflecting 5 percent higher volume, partly offset by 1 percent lower local selling prices and a 1 percent negative currency impact.   The table below shows full year regional sales and variances versus full year 2012.

 

 

 

12 Months Ended
December 31, 2013

 

Percentage Change Due to:

 

 

 

(Dollars in millions)

 

$

 

% Change

 

Local
Price

 

Currency
Effect

 

Volume

 

Portfolio/
Other

 

U.S. & Canada

 

$

14,788

 

4

 

1

 

 

3

 

 

EMEA*

 

8,379

 

4

 

(2

)

1

 

4

 

1

 

Asia Pacific

 

7,775

 

(3

)

(6

)

(3

)

6

 

 

Latin America

 

4,792

 

6

 

 

(3

)

9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Consolidated Sales

 

$

35,734

 

3

 

(1

)

(1

)

5

 

 

 


* Europe, Middle East & Africa

 

4



 

Segment Sales — Full Year

 

The table below shows full-year 2013 segment sales with related variances versus the prior year.

 

 

 

12 Months Ended
December 31, 2013

 

Percentage Change
Due to:

 

SEGMENT SALES
(Dollars in millions)

 

$

 

% Change

 

USD
Price

 

Volume

 

Portfolio/
Other

 

Agriculture

 

$

11,739

 

13

 

5

 

7

 

1

 

Electronics & Communications

 

2,549

 

(6

)

(8

)

2

 

 

Industrial Biosciences

 

1,224

 

4

 

2

 

2

 

 

Nutrition & Health

 

3,473

 

1

 

3

 

 

(2

)

Performance Chemicals

 

6,703

 

(7

)

(12

)

5

 

 

Performance Materials

 

6,468

 

 

(3

)

4

 

(1

)

Safety & Protection

 

3,884

 

2

 

(1

)

3

 

 

Other

 

6

 

nm

 

 

 

 

 

 

 

Total segment sales

 

36,046

 

 

 

 

 

 

 

 

 

Elimination of transfers

 

(312

)

 

 

 

 

 

 

 

 

Consolidated net sales

 

$

35,734

 

 

 

 

 

 

 

 

 

 

Operating Earnings — Full Year

 

 

 

 

 

 

 

Change vs. 2012

 

(Dollars in millions)

 

FY 2013

 

FY 2012

 

$

 

%

 

Agriculture

 

$

2,483

 

$

2,138

 

$

345

 

16

%

Electronics & Communications

 

334

 

259

 

75

 

29

%

Industrial Biosciences

 

169

 

162

 

7

 

4

%

Nutrition & Health

 

299

 

319

 

(20

)

-6

%

Performance Chemicals

 

998

 

1,814

 

(816

)

-45

%

Performance Materials

 

1,297

 

1,225

 

72

 

6

%

Safety & Protection

 

690

 

620

 

70

 

11

%

Other

 

(377

)

(348

)

(29

)

nm

 

 

 

5,893

 

6,189

 

(296

)

-5

%

Pharmaceuticals

 

32

 

62

 

(30

)

-48

%

Total segment operating earnings (1)

 

5,925

 

6,251

 

(326

)

-5

%

 

 

 

 

 

 

 

 

 

 

Corporate expenses

 

(762

)

(864

)

102

 

nm

 

Interest expense

 

(448

)

(464

)

16

 

nm

 

Operating earnings before income taxes and exchange gains/losses

 

4,715

 

4,923

 

(208

)

-4

%

Provision for income taxes on operating earnings, excluding taxes on exchange gains/losses

 

(983

)

(1,190

)

207

 

nm

 

Net after-tax exchange gains (losses) (2)

 

(86

)

(142

)

56

 

nm

 

Net income attributable to noncontrolling interests

 

(14

)

(25

)

11

 

nm

 

Operating earnings

 

$

3,632

 

$

3,566

 

$

66

 

2

%

 

 

 

 

 

 

 

 

 

 

Operating earnings per share

 

$

3.88

 

$

3.77

 

$

0.11

 

3

%

 


(1)  See Schedules B and C for listing of significant items and their impact by segment.

(2)  See Schedule D for additional information on exchange gains and losses.

 

5



 

The following is a summary of business results for each of the company’s reportable segments comparing fourth quarter with the prior year, unless otherwise noted. References to selling price are on a U.S. dollar basis, including the impact of currency.

 

Agriculture — Operating earnings were $88 million compared to a seasonal operating loss of $77 million in last year’s fourth quarter.  The improvement was driven by strong insecticide sales in Latin America, earlier seed shipments for the Brazil safrinha corn season enabled by recent investments, and earlier direct seed shipments to North American farmers, partially offset by negative currency impact.  As a result of the earlier timing of seed shipments, about $100 million of operating earnings were realized in the fourth quarter versus the first quarter 2014.

 

Full year operating earnings of $2.5 billion grew 16 percent on 13 percent higher sales, partially offset by higher seed input costs and negative currency impact.  Sales growth was principally driven by higher global seed prices and volumes, increased global insecticide and fungicide volumes, and the benefit of increased ownership in Pannar.

 

Electronics & Communications — Operating earnings of $93 million increased $50 million driven by higher sales volume and improved plant utilization.  Higher volume, mainly in photovoltaic markets reflecting demand improvement and share gains, was offset in part by reduced selling prices, largely from pass-through of lower metals prices.

 

Industrial Biosciences — Operating earnings of $40 million were essentially flat on increased demand for Sorona® polymer for carpeting and apparel and enzymes for ethanol production, offset by higher costs.

 

Nutrition & Health — Operating earnings of $81 million increased $23 million driven by pricing gains and increased demand in protein solutions, probiotics and cultures.  Operating margin improved more than two points as pricing gains, mix enrichment and productivity actions more than offset growth investments.

 

Performance Chemicals — Operating earnings of $229 million were down 3 percent as price declines for titanium dioxide and refrigerants, along with higher raw material costs, more than offset volume increases and improved plant utilization in both businesses. Titanium dioxide volume was up 18 percent from fourth quarter 2012.

 

Performance Materials — Operating earnings of $295 million increased $22 million reflecting higher volume from increased demand in packaging, automotive, and industrial markets, partially offset by lower selling prices and higher raw material costs.

 

Safety & Protection — Operating earnings of $209 million increased $76 million due primarily to continued productivity improvements, improved plant utilization, and higher volume, primarily in industrial markets.

 

Additional information is available on the DuPont Investor Center website at http://www.investors.dupont.com.

 

Outlook

 

The company expects full-year 2014 operating earnings of $4.20 to $4.45 per share, up 8 to 15 percent versus 2013, with full-year 2014 sales increasing 4 percent to about $37 billion, including about a 2 percent decline from portfolio changes.  The outlook reflects an expectation for continuing improvement in global industrial production, lower agricultural input costs, and a slightly stronger average exchange value for the U.S. dollar.  This outlook also recognizes that Agriculture earnings of approximately $.09 per share that historically would have been earned in the first quarter 2014 were realized in the fourth quarter 2013 due to earlier timing of seed shipments.

 

6



 

Use of Non-GAAP Measures

 

Management believes that certain non-GAAP measurements are meaningful to investors because they provide insight with respect to ongoing operating results of the company.  Such measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance.  Reconciliations of non-GAAP measures to GAAP are provided in schedules A, C and D.

 

DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802.  The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment.  For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.

 

Forward-Looking Statements:  This news release contains forward-looking statements which may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “anticipates” or other words of similar meaning.  All statements that address expectations or projections about the future, including statements about the company’s growth strategy, product development, regulatory approval, market position, anticipated benefits of acquisitions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements.  Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized.  Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control.  Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; significant litigation and environmental matters; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters; ability to protect and enforce the company’s intellectual property rights; successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses and successful completion of the proposed spinoff of the Performance Chemicals segment including ability to fully realize the expected benefits of the proposed spinoff.  The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.

 

#   #   #

 

01/28/14

 

7



 

E. I. du Pont de Nemours and Company

Consolidated Income Statements

(Dollars in millions, except per share amounts)

 

SCHEDULE A

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

 

2013

 

2012

 

2013

 

2012

 

Net sales

 

$

7,747

 

$

7,325

 

$

35,734

 

$

34,812

 

Other income, net (a)

 

89

 

247

 

410

 

498

 

Total

 

7,836

 

7,572

 

36,144

 

35,310

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

5,133

 

4,980

 

22,548

 

21,538

 

Other operating charges (a)

 

995

 

1,013

 

3,838

 

4,077

 

Selling, general and administrative expenses

 

814

 

836

 

3,554

 

3,527

 

Research and development expense

 

550

 

561

 

2,153

 

2,123

 

Interest expense

 

108

 

117

 

448

 

464

 

Employee separation / asset related charges, net (a)

 

114

 

99

 

114

 

493

 

Total

 

7,714

 

7,606

 

32,655

 

32,222

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations before income taxes

 

122

 

(34

)

3,489

 

3,088

 

(Benefit from) provision for income taxes on continuing operations (a)

 

(61

)

(38

)

626

 

616

 

Income from continuing operations after income taxes

 

183

 

4

 

2,863

 

2,472

 

Income from discontinued operations after taxes

 

2

 

89

 

1,999

 

308

 

 

 

 

 

 

 

 

 

 

 

Net income

 

185

 

93

 

4,862

 

2,780

 

 

 

 

 

 

 

 

 

 

 

Less: Net income attributable to noncontrolling interests

 

 

1

 

14

 

25

 

 

 

 

 

 

 

 

 

 

 

Net income attributable to DuPont

 

$

185

 

$

92

 

$

4,848

 

$

2,755

 

 

 

 

 

 

 

 

 

 

 

Basic earnings per share of common stock (b):

 

 

 

 

 

 

 

 

 

Basic earnings per share of common stock from continuing operations

 

$

0.19

 

$

 

$

3.07

 

$

2.61

 

Basic earnings per share of common stock from discontinued operations

 

 

0.09

 

2.16

 

0.33

 

Basic earnings per share of common stock

 

$

0.20

 

$

0.10

 

$

5.22

 

$

2.94

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share of common stock (b):

 

 

 

 

 

 

 

 

 

Diluted earnings per share of common stock from continuing operations

 

$

0.19

 

$

 

$

3.04

 

$

2.59

 

Diluted earnings per share of common stock from discontinued operations

 

 

0.09

 

2.14

 

0.33

 

Diluted earnings per share of common stock

 

$

0.20

 

$

0.09

 

$

5.18

 

$

2.91

 

 

 

 

 

 

 

 

 

 

 

Dividends per share of common stock

 

$

0.45

 

$

0.43

 

$

1.78

 

$

1.70

 

 

 

 

 

 

 

 

 

 

 

Average number of shares outstanding used in earnings per share (EPS) calculation:

 

 

 

 

 

 

 

 

 

Basic

 

927,279,000

 

933,420,000

 

925,984,000

 

933,275,000

 

Diluted

 

934,949,000

 

941,219,000

 

933,147,000

 

942,197,000

 

 


(a) See Schedule B for detail of significant items.

(b) The sum of the individual earnings per share amounts may not equal the total due to rounding.

 

Reconciliation of Non-GAAP Measures

 

Summary of Earnings Comparison

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

 

2013

 

2012

 

%
Change

 

2013

 

2012

 

%
Change

 

Income from continuing operations after income taxes (GAAP)

 

$

183

 

$

4

 

4475

%

$

2,863

 

$

2,472

 

16

%

Less: Significant items benefit (charge) included in income from continuing operations after income taxes (per Schedule B)

 

(294

)

(91

)

 

 

(423

)

(680

)

 

 

Non-operating pension/OPEB costs included in income from continuing operations after income taxes

 

(81

)

(99

)

 

 

(360

)

(439

)

 

 

Net income attributable to noncontrolling interest

 

 

1

 

 

 

14

 

25

 

 

 

Operating earnings

 

$

558

 

$

193

 

189

%

$

3,632

 

$

3,566

 

2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EPS from continuing operations (GAAP)

 

$

0.19

 

$

 

n/a

 

$

3.04

 

$

2.59

 

17

%

Significant items benefit (charge) included in EPS (per Schedule B)

 

(0.31

)

(0.09

)

 

 

(0.45

)

(0.72

)

 

 

Non-operating pension/OPEB costs included in EPS

 

(0.09

)

(0.11

)

 

 

(0.39

)

(0.46

)

 

 

Operating EPS

 

$

0.59

 

$

0.20

 

195

%

$

3.88

 

$

3.77

 

3

%

 

8



 

E. I. du Pont de Nemours and Company

Condensed Consolidated Balance Sheets

(Dollars in millions, except per share amounts)

 

SCHEDULE A (continued)

 

 

 

December 31,
2013

 

December 31,
2012

 

Assets

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

 

$

8,941

 

$

4,284

 

Marketable securities

 

145

 

123

 

Accounts and notes receivable, net

 

6,047

 

5,452

 

Inventories

 

8,042

 

7,565

 

Prepaid expenses

 

206

 

204

 

Deferred income taxes

 

775

 

613

 

Assets held for sale

 

228

 

3,076

 

Total current assets

 

24,384

 

21,317

 

Property, plant and equipment, net of accumulated depreciation (December 31, 2013 - $19,438; December 31, 2012 - $19,085)

 

12,993

 

12,741

 

Goodwill

 

4,713

 

4,616

 

Other intangible assets

 

5,096

 

5,126

 

Investment in affiliates

 

1,011

 

1,163

 

Deferred income taxes

 

2,353

 

3,936

 

Other assets

 

949

 

960

 

Total

 

$

51,499

 

$

49,859

 

 

 

 

 

 

 

Liabilities and Equity

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable

 

$

5,180

 

$

4,853

 

Short-term borrowings and capital lease obligations

 

1,721

 

1,275

 

Income taxes

 

247

 

343

 

Other accrued liabilities

 

6,219

 

5,997

 

Liabilities related to assets held for sale

 

 

1,084

 

Total current liabilities

 

13,367

 

13,552

 

Long-term borrowings and capital lease obligations

 

10,741

 

10,465

 

Other liabilities

 

10,179

 

14,687

 

Deferred income taxes

 

926

 

856

 

Total liabilities

 

35,213

 

39,560

 

 

 

 

 

 

 

Commitments and contingent liabilities

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

Preferred stock

 

237

 

237

 

Common stock, $0.30 par value; 1,800,000,000 shares authorized; Issued at December 31, 2013 - 1,014,027,000 ; December 31, 2012 - 1,020,057,000

 

304

 

306

 

Additional paid-in capital

 

11,072

 

10,655

 

Reinvested earnings

 

16,784

 

14,383

 

Accumulated other comprehensive loss

 

(5,441

)

(8,646

)

Common stock held in treasury, at cost (87,041,000 shares at December 31, 2013 and December 31, 2012)

 

(6,727

)

(6,727

)

Total DuPont stockholders’ equity

 

16,229

 

10,208

 

Noncontrolling interests

 

57

 

91

 

Total equity

 

16,286

 

10,299

 

Total

 

$

51,499

 

$

49,859

 

 

9



 

E. I. du Pont de Nemours and Company

Condensed Consolidated Statement of Cash Flows

(Dollars in millions)

 

SCHEDULE A (continued)

 

 

 

Twelve Months Ended
December 31,

 

 

 

2013

 

2012

 

Total Company

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

4,862

 

$

2,780

 

Adjustments to reconcile net income to cash used for operating activities:

 

 

 

 

 

Depreciation

 

1,280

 

1,376

 

Amortization

 

323

 

337

 

Other operating charges and credits - net

 

859

 

1,185

 

Gain on sale of business

 

(2,687

)

 

Contributions to pension plans

 

(313

)

(848

)

Change in operating assets and liabilities - net

 

(1,145

)

19

 

Cash provided by operating activities

 

3,179

 

4,849

 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

Purchases of property, plant and equipment

 

(1,882

)

(1,793

)

Investments in affiliates

 

(58

)

(97

)

Payments for businesses - net of cash acquired

 

(133

)

(18

)

Proceeds from sale of business - net

 

4,841

 

 

Proceeds from sales of assets - net

 

142

 

302

 

Net (increase) decrease in short-term financial instruments

 

(45

)

315

 

Forward exchange contract settlements

 

40

 

(40

)

Other investing activities - net

 

40

 

(15

)

Cash provided by (used for) investing activities

 

2,945

 

(1,346

)

 

 

 

 

 

 

Financing activities

 

 

 

 

 

Dividends paid to stockholders

 

(1,661

)

(1,594

)

Net increase (decrease) in borrowings

 

717

 

(793

)

Repurchase of common stock

 

(1,000

)

(400

)

Proceeds from exercise of stock options

 

536

 

550

 

Payments for noncontrolling interest

 

(65

)

(470

)

Other financing activities - net

 

(1

)

10

 

Cash used for financing activities

 

(1,474

)

(2,697

)

 

 

 

 

 

 

Effect of exchange rate changes on cash

 

(88

)

(13

)

 

 

 

 

 

 

Cash classified as held for sale

 

 

(95

)

 

 

 

 

 

 

Increase in cash and cash equivalents

 

4,562

 

698

 

 

 

 

 

 

 

Cash and cash equivalents at beginning of period

 

4,379

 

3,586

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

$

8,941

 

$

4,284

 

 

Reconciliation of Non-GAAP Measure

 

Calculation of Free Cash Flow - Total Company

 

 

 

Twelve Months Ended
December 31,

 

 

 

2013

 

2012

 

Cash provided by operating activities

 

$

3,179

 

$

4,849

 

Purchases of property, plant and equipment

 

(1,882

)

(1,793

)

Free cash flow

 

$

1,297

 

$

3,056

 

 

10



 

E. I. du Pont de Nemours and Company

Schedule of Significant Items from Continuing Operations

(Dollars in millions, except per share amounts)

 

SCHEDULE B

 

SIGNIFICANT ITEMS FROM CONTINUING OPERATIONS

 

 

 

Pre-tax

 

After-tax

 

($ Per Share)

 

 

 

2013

 

2012

 

2013

 

2012

 

2013

 

2012

 

1st Quarter

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer claims charge (a)

 

$

(35

)

$

(50

)

$

(22

)

$

(32

)

$

(0.02

)

$

(0.04

)

Income tax items (b)

 

 

 

42

 

 

0.04

 

 

1st Quarter - Total

 

$

(35

)

$

(50

)

$

20

 

$

(32

)

$

0.02

 

$

(0.04

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2nd Quarter

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer claims charge (a)

 

$

(80

)

$

(265

)

$

(51

)

$

(169

)

$

(0.05

)

$

(0.18

)

Income tax items (c)

 

(11

)

 

(27

)

 

(0.03

)

 

Litigation settlement (d)

 

 

(137

)

 

(123

)

 

(0.13

)

Gain on sale of equity method investment (e)

 

 

122

 

 

77

 

 

0.08

 

2nd Quarter - Total

 

$

(91

)

$

(280

)

$

(78

)

$

(215

)

$

(0.08

)

$

(0.23

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3rd Quarter

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer claims charge (a)

 

$

(40

)

$

(125

)

$

(24

)

$

(80

)

$

(0.03

)

$

(0.09

)

Litigation settlement (f)

 

(72

)

 

(47

)

 

(0.05

)

 

Restructuring charge (g)

 

 

(152

)

 

(105

)

 

(0.11

)

Asset impairment charge (h)

 

 

(242

)

 

(157

)

 

(0.17

)

3rd Quarter - Total

 

$

(112

)

$

(519

)

$

(71

)

$

(342

)

$

(0.08

)

$

(0.37

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4th Quarter

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer claims charge (a)

 

$

(197

)

$

(135

)

$

(129

)

$

(89

)

$

(0.13

)

$

(0.09

)

Restructuring charge/adjustments (i)

 

5

 

(66

)

3

 

(56

)

 

(0.06

)

Asset impairment charge (h)

 

(129

)

(33

)

(168

)

(21

)

(0.18

)

(0.02

)

Gain on sale of a business (j)

 

 

117

 

 

75

 

 

0.08

 

4th Quarter - Total

 

$

(321

)

$

(117

)

$

(294

)

$

(91

)

$

(0.31

)

$

(0.09

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Full Year - Total (k)

 

$

(559

)

$

(966

)

$

(423

)

$

(680

)

$

(0.45

)

$

(0.72

)

 

11



 

E. I. du Pont de Nemours and Company

Schedule of Significant Items from Continuing Operations

(Dollars in millions, except per share amounts)

 

SCHEDULE B (continued)

 


(a)

Fourth quarter 2013 included a net charge of $(197) consisting of a $(245) charge associated with the company’s process to fairly resolve claims related to the use of Imprelis® herbicide offset by $48 of insurance recoveries. At December 31, 2013, the company had recorded charges of $(1,175) which represents the company’s best estimate of the loss associated with resolving these claims. The company had accruals of $489 related to these claims at December 31, 2013. The company has an applicable insurance program with a deductible equal to the first $100 of costs and expenses. The insurance program limits are $725 for costs and expenses in excess of the $100. The company has submitted and will continue to submit requests for payment to its insurance carriers for costs associated with this matter. The company has begun to receive payment from its insurance carriers and continues to seek recovery although the timing and outcome remain uncertain. These charges are recorded in Other operating charges and relate to the Agriculture segment.

 

 

(b)

First quarter 2013 included a net tax benefit of $42 consisting of a $68 benefit for the 2013 extension of certain U.S business tax provisions offset by a ($26) charge related to the global distribution of Performance Coatings cash proceeds.

 

 

(c)

Second quarter 2013 included a charge of ($11) in Other income, net related to interest on a prior year tax position. Second quarter 2013 also included a charge of ($49) associated with a change in accrual for a prior year tax position (inclusive of a benefit associated with interest on a prior year tax position) offset by a $33 benefit for an enacted tax law change.

 

 

(d)

Second quarter 2012 included a charge of ($137) recorded in Other operating charges primarily related to the company’s settlement of litigation with Invista. This matter is recorded in the Other segment.

 

 

(e)

Second quarter 2012 included a pre-tax gain of $122 recorded in Other income, net associated with the sale of an equity method investment in the Electronics & Communications segment.

 

 

(f)

Third quarter 2013 included a charge of $(72) recorded in Other operating charges related to the company’s settlement of titanium dioxide antitrust litigation. This matter relates to the Performance Chemicals segment.

 

 

(g)

Third quarter 2012 included a $(152) restructuring charge recorded in Employee separation/asset related charges, net consisting of $133 of severance and related benefit costs and $19 of asset related charges as a result of the company’s plan to eliminate corporate costs previously allocated to Performance Coatings and cost-cutting actions to improve competitiveness. Pre-tax charges by segment were: Agriculture - $(3), Nutrition & Health - $(13), Electronics & Communications - $(7), Performance Chemicals - $(3), Performance Materials - $(9), Safety & Protection - $(55), Industrial Biosciences - $(3), and Corporate expenses - $(59).

 

 

(h)

Fourth quarter 2013 and third quarter 2012 included impairment charges of $(129) and $(150), respectively, recorded in Employee separation/asset related charges, net related to an asset grouping within the Electronics & Communications segment. The fourth quarter 2013 charge was the result of strategic decisions related to the thin film photovoltaic market and the third quarter 2012 charge was a result of deteriorating conditions in the thin film photovoltaic market. Fourth quarter 2012 included a $(33) impairment charge recorded in Employee separation/asset related charges, net related to an asset group within the Performance Chemicals segment. The charge was a result of strategic decisions related to deteriorating conditions within a specific industrial chemicals market. Third quarter 2012 included a $(92) impairment charge within Performance Materials as a result of deteriorating conditions in an industrial polymer market.

 

 

(i)

Fourth quarter 2013 included a net $5 restructuring adjustment consisting of a $24 benefit associated with prior year restructuring programs and a $(19) charge associated with restructuring actions related to a joint venture. The majority of the $24 net reduction recorded in Employee separation/asset related charges, net was due to the achievement of work force reductions through non-severance programs associated with the 2012 restructuring program. The charge of $(19) included $(9) recorded in Employee separation/asset related charges, net and $(10) recorded in Other income, net and was the result of restructuring actions related to a joint venture within the Performance Materials segment. Pre-tax amounts by segment were: Agriculture - $1, Electronics & Communications - $(2), Industrial Biosciences - $1, Nutrition & Health - $6, Performance Chemicals - $(2), Performance Materials - $(16), Safety & Protection - $4, Other - $5, and Corporate - $8. Fourth quarter 2012 included a $(66) restructuring charge recorded in Employee separation/asset related charges, net primarily as a result of the company’s plans to eliminate corporate costs previously allocated to Performance Coatings and cost-cutting actions to improve competitiveness, partially offset by a reversal of prior year restructuring accruals. Pre-tax charges by segment are: Agriculture - $(8), Electronics & Communications - $(2), Nutrition & Health - $(36), Performance Materials - $(3), Safety & Protection - $(3), Other - $11, and Corporate expenses - $(25).

 

 

(j)

Fourth quarter 2012 included a pre-tax gain of $117 recorded in Other income, net associated with the sale of a business in the Agriculture segment.

 

 

(k)

Earnings per share for the year may not equal the sum of quarterly earnings per share due to changes in average share calculations.

 

12


 

 


 

E. I. du Pont de Nemours and Company

Consolidated Segment Information

(Dollars in millions)

 

SCHEDULE C

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

 

2013

 

2012

 

2013

 

2012

 

SEGMENT SALES (1)

 

 

 

 

 

 

 

 

 

Agriculture

 

$

1,806

 

$

1,535

 

$

11,739

 

$

10,426

 

Electronics & Communications

 

642

 

622

 

2,549

 

2,701

 

Industrial Biosciences

 

326

 

300

 

1,224

 

1,180

 

Nutrition & Health

 

872

 

853

 

3,473

 

3,422

 

Performance Chemicals

 

1,616

 

1,588

 

6,703

 

7,188

 

Performance Materials

 

1,576

 

1,534

 

6,468

 

6,447

 

Safety & Protection

 

975

 

964

 

3,884

 

3,825

 

Other

 

1

 

1

 

6

 

5

 

Total Segment sales

 

7,814

 

7,397

 

36,046

 

35,194

 

 

 

 

 

 

 

 

 

 

 

Elimination of transfers

 

(67

)

(72

)

(312

)

(382

)

Consolidated net sales

 

$

7,747

 

$

7,325

 

$

35,734

 

$

34,812

 

 


(1)   Sales for the reporting segments include transfers.

 

13



 

E. I. du Pont de Nemours and Company

Consolidated Segment Information

(Dollars in millions)

 

SCHEDULE C (continued)

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

 

2013

 

2012

 

2013

 

2012

 

INCOME/(LOSS) FROM CONTINUING OPERATIONS (GAAP)

 

 

 

 

 

 

 

 

 

Agriculture

 

$

(108

)

$

(103

)

$

2,132

 

$

1,669

 

Electronics & Communications

 

(38

)

41

 

203

 

222

 

Industrial Biosciences

 

41

 

41

 

170

 

159

 

Nutrition & Health

 

87

 

22

 

305

 

270

 

Performance Chemicals

 

227

 

203

 

924

 

1,778

 

Performance Materials

 

279

 

270

 

1,281

 

1,121

 

Safety & Protection

 

213

 

130

 

694

 

562

 

Pharmaceuticals

 

5

 

9

 

32

 

62

 

Other

 

(96

)

(89

)

(372

)

(474

)

Total Segment PTOI

 

610

 

524

 

5,369

 

5,369

 

 

 

 

 

 

 

 

 

 

 

Corporate expenses

 

(183

)

(240

)

(765

)

(948

)

Interest expense

 

(108

)

(117

)

(448

)

(464

)

Non-operating pension/OPEB costs

 

(124

)

(147

)

(539

)

(654

)

Net exchange gains (losses) (1)

 

(73

)

(54

)

(128

)

(215

)

Income (loss) before income taxes from continuing operations

 

$

122

 

$

(34

)

$

3,489

 

$

3,088

 

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

 

2013

 

2012

 

2013

 

2012

 

SIGNIFICANT ITEMS BY SEGMENT (PRE-TAX) (2)

 

 

 

 

 

 

 

 

 

Agriculture

 

$

(196

)

$

(26

)

$

(351

)

$

(469

)

Electronics & Communications

 

(131

)

(2

)

(131

)

(37

)

Industrial Biosciences

 

1

 

 

1

 

(3

)

Nutrition & Health

 

6

 

(36

)

6

 

(49

)

Performance Chemicals

 

(2

)

(33

)

(74

)

(36

)

Performance Materials

 

(16

)

(3

)

(16

)

(104

)

Safety & Protection

 

4

 

(3

)

4

 

(58

)

Pharmaceuticals

 

 

 

 

 

Other

 

5

 

11

 

5

 

(126

)

Total significant items by segment

 

(329

)

(92

)

(556

)

(882

)

Corporate expenses

 

8

 

(25

)

(3

)

(84

)

Total significant items before income taxes

 

$

(321

)

$

(117

)

$

(559

)

$

(966

)

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

 

2013

 

2012

 

2013

 

2012

 

OPERATING EARNINGS

 

 

 

 

 

 

 

 

 

Agriculture

 

$

88

 

$

(77

)

$

2,483

 

$

2,138

 

Electronics & Communications

 

93

 

43

 

334

 

259

 

Industrial Biosciences

 

40

 

41

 

169

 

162

 

Nutrition & Health

 

81

 

58

 

299

 

319

 

Performance Chemicals

 

229

 

236

 

998

 

1,814

 

Performance Materials

 

295

 

273

 

1,297

 

1,225

 

Safety & Protection

 

209

 

133

 

690

 

620

 

Pharmaceuticals

 

5

 

9

 

32

 

62

 

Other

 

(101

)

(100

)

(377

)

(348

)

Total segment operating earnings

 

939

 

616

 

5,925

 

6,251

 

Corporate expenses

 

(191

)

(215

)

(762

)

(864

)

Interest expense

 

(108

)

(117

)

(448

)

(464

)

Operating earnings before income taxes and exchange gains (losses)

 

640

 

284

 

4,715

 

4,923

 

Net exchange gains (losses) (1)

 

(73

)

(54

)

(128

)

(215

)

Operating earnings before income taxes

 

$

567

 

$

230

 

$

4,587

 

$

4,708

 

 


(1)  See Schedule D for additional information on exchange gains and losses.

(2)  See Schedule B for detail of significant items.

 

14



 

E. I. du Pont de Nemours and Company

Reconciliation of Non-GAAP Measures

(Dollars in millions, except per share amounts)

 

SCHEDULE D

 

Reconciliations of Adjusted EBIT / EBITDA to Consolidated Income Statements

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

 

2013

 

2012

 

2013

 

2012

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations before income taxes

 

$

122

 

$

(34

)

$

3,489

 

$

3,088

 

Add: Significant items before income taxes

 

321

 

117

 

559

 

966

 

Add: Non-operating pension/OPEB costs

 

124

 

147

 

539

 

654

 

Operating earnings before income taxes

 

$

567

 

$

230

 

$

4,587

 

$

4,708

 

Less: Net income attributable to noncontrolling interests

 

 

1

 

14

 

25

 

Add: Interest expense

 

108

 

117

 

448

 

464

 

Adjusted EBIT from operating earnings

 

675

 

346

 

5,021

 

5,147

 

Add: Depreciation and amortization

 

387

 

394

 

1,603

 

1,631

 

Adjusted EBITDA from operating earnings

 

$

1,062

 

$

740

 

$

6,624

 

$

6,778

 

 

Reconciliation of Operating Earnings Per Share (EPS) Outlook

 

The reconciliation below represents the company’s outlook on an operating earnings basis, defined as earnings from continuing operations excluding significant items and non-operating pension/OPEB costs.

 

 

 

Year Ended December 31,

 

 

 

2014 Outlook

 

2013 Actual

 

Operating EPS

 

$4.20 - $4.45

 

$

3.88

 

 

 

 

 

 

 

Significant items

 

 

 

 

 

Tax items

 

 

 

0.02

 

Customer claims charges

 

 

 

(0.24

)

Restructuring charge/adjustments

 

 

 

 

Litigation settlement

 

 

 

(0.05

)

Asset impairment charge

 

 

 

(0.18

)

 

 

 

 

 

 

Non-operating pension/OPEB costs - estimate

 

(0.09

)

(0.39

)

 

 

 

 

 

 

EPS from continuing operations (GAAP)

 

$4.11 - $4.36

 

$

3.04

 

 

2014 Operating EPS excludes the potential gain on sale of Glass Laminating Solutions/Vinyls and anticipated costs associated with the separation of the Performance Chemicals segment.

 

15



 

E. I. du Pont de Nemours and Company

Reconciliation of Non-GAAP Measures

(Dollars in millions)

 

SCHEDULE D (continued)

 

Exchange Gains/Losses on Operating Earnings

 

The company routinely uses forward exchange contracts to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its operations. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes. The net pre-tax exchange gains and losses are recorded in Other income, net and the related tax impact is recorded in Provision for (benefit from) income taxes on the Consolidated Income Statements.

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

 

2013

 

2012

 

2013

 

2012

 

Subsidiary/Affiliate Monetary Position Gain (Loss)

 

 

 

 

 

 

 

 

 

Pre-tax exchange gains (losses) (includes equity affiliates)

 

$

(42

)

$

(8

)

$

(163

)

$

(58

)

Local tax benefits (expenses)

 

22

 

9

 

54

 

19

 

Net after-tax impact from subsidiary exchange gains (losses)

 

$

(20

)

$

1

 

$

(109

)

$

(39

)

 

 

 

 

 

 

 

 

 

 

Hedging Program Gain (Loss)

 

 

 

 

 

 

 

 

 

Pre-tax exchange gains (losses)

 

$

(31

)

$

(46

)

$

35

 

$

(157

)

Tax benefits (expenses)

 

12

 

16

 

(12

)

54

 

Net after-tax impact from hedging program exchange gains (losses)

 

$

(19

)

$

(30

)

$

23

 

$

(103

)

 

 

 

 

 

 

 

 

 

 

Total Exchange Gain (Loss)

 

 

 

 

 

 

 

 

 

Pre-tax exchange gains (losses)

 

$

(73

)

$

(54

)

$

(128

)

$

(215

)

Tax benefits (expenses)

 

34

 

25

 

42

 

73

 

Net after-tax exchange gains (losses) (1)

 

$

(39

)

$

(29

)

$

(86

)

$

(142

)

 

As shown above, the “Total Exchange Gain (Loss)” is the sum of the “Subsidiary/Affiliate Monetary Position Gain (Loss)” and the “Hedging Program Gain (Loss).”

 


(1)  The above Net after-tax exchange gains (losses) excludes gains (losses) attributable to discontinued operations of $0 and $(3) for the three months ended December 31, 2013 and 2012, respectively, and $(5) and $(14) for the twelve months ended December 31, 2013 and 2012, respectively.

 

Reconciliation of Base Income Tax Rate to Effective Income Tax Rate

 

Base income tax rate is defined as the effective income tax rate less the effect of exchange gains (losses), as defined above, significant items and non-operating pension/OPEB costs.

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

 

2013

 

2012

 

2013

 

2012

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations before income taxes

 

$

122

 

$

(34

)

$

3,489

 

$

3,088

 

Add: Significant items - (benefit) charge (2)

 

321

 

117

 

559

 

966

 

Non-operating pension/OPEB costs

 

124

 

147

 

539

 

654

 

Less: Net exchange (losses) gains

 

(73

)

(54

)

(128

)

(215

)

Income from continuing operations before income taxes, significant items, exchange gains (losses), and non-operating pension/OPEB costs

 

$

640

 

$

284

 

$

4,715

 

$

4,923

 

 

 

 

 

 

 

 

 

 

 

(Benefit from) provision for income taxes on continuing operations

 

$

(61

)

$

(38

)

$

626

 

$

616

 

Add: Tax benefits (expenses) on significant items

 

27

 

26

 

136

 

286

 

Tax benefits (expenses) on non-operating pension/OPEB costs

 

43

 

48

 

179

 

215

 

Tax benefits (expenses) on exchange gains/losses

 

34

 

25

 

42

 

73

 

Provision for income taxes on operating earnings, excluding exchange gains (losses)

 

$

43

 

$

61

 

$

983

 

$

1,190

 

 

 

 

 

 

 

 

 

 

 

Effective income tax rate

 

(50.0

)%

111.8

%

17.9

%

19.9

%

Significant items effect and non-operating pension/OPEB costs effect

 

51.6

%

(96.1

)%

2.6

%

3.8

%

Tax rate, from continuing operations, before significant items and non-operating pension/OPEB costs

 

1.6

%

15.7

%

20.5

%

23.7

%

Exchange gains (losses) effect

 

5.1

%

5.8

%

0.3

%

0.4

%

Base income tax rate from continuing operations

 

6.7

%

21.5

%

20.8

%

24.2

%

 


(2)  See Schedule B for detail of significant items.

 

16